Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology (CSBR) reported first quarter fiscal 2027 oncology revenue of $15.2 million, up 8.8% year over year, for the period ended July 31, 2026.
Oncology services margin expanded to 51% from 43%, driven by higher core research services and data license revenue and lower third-party radiolabeling costs. Adjusted EBITDA rose to $671,000 from $59,000, and non-GAAP basic EPS increased to $0.05 from $0.01. GAAP net loss narrowed slightly to $426,000, or $0.03 per basic share. Total costs and operating expenses increased 7.7% to $15.6 million, reflecting higher sales and marketing, R&D, and G&A.
Cash used in operating activities was $492,000, versus $600,000 provided in the prior-year quarter. The company ended the quarter with $4.4 million in cash, no debt, total assets of $33.3 million, and total liabilities of $28.8 million.
Champions Oncology (CSBR) will report financial and operational results for the quarter ended July 31, 2026 on Thursday, September 10, 2026, after market close.
The company will host a conference call at 4:30 P.M. EDT (1:30 P.M. PDT). Participants can join via domestic dial-in 888-506-0062 or international 973-528-0011 using access code 938837. A replay will be available by phone and via the investors section of the company website.
Champions Oncology (NASDAQ: CSBR) announced an expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities at its U.S.-based facility. The enhancement connects longitudinal in vivo imaging of radiopharmaceutical uptake with terminal biodistribution, efficacy readouts and clinically annotated patient-derived xenograft (PDX) tumor biology in a single workflow.
The platform now combines high-resolution SPECT/CT using the Molecubes γ-X CUBE micro-SPECT/CT system, access to PDX and CDX oncology models, integrated radiolabeling services, and a broad panel of alpha- and beta-emitting isotopes, including newly added Radium-224/Lead-212 Generator and Terbium-161, supported by expert study design and data interpretation.
Champions Oncology (Nasdaq: CSBR) reported record fiscal 2026 oncology revenue of $59.4 million, up 4% from $56.9 million, despite the non-recurrence of roughly $4.5 million of prior-year data license revenue. Fourth-quarter revenue rose 12% year over year to $13.8 million, with oncology services margin improving to 51% from 41%.
The company posted a fiscal 2026 loss from operations of $1.1 million versus income of $4.6 million last year, as operating expenses increased to $60.6 million driven by outsourced radiopharmaceutical costs and investments in its commercial organization and data platform. Adjusted EBITDA was $1.6 million for the year and $158,000 in Q4, marking positive Adjusted EBITDA in all four quarters. Champions ended the year with $4.9 million in cash and no debt.
Champions Oncology (NASDAQ:CSBR) will report its financial and operational results for the fourth quarter and year ended April 30, 2026 on Monday, July 27, 2026, after market close. Management will discuss the results on a conference call that day at 4:30 P.M. ET (1:30 P.M. PT).
Investors can join the call by dialing 888-506-0062 (Domestic) or 973-528-0011 (International) with access code 347142. A replay will be available at 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 54320, and in the investors section of the company’s website within 72 hours. According to Champions Oncology, the company provides global preclinical and clinical oncology research services and data platforms to biopharma organizations.
Champions Oncology (NASDAQ:CSBR) will present eight poster studies at the AACR Annual Meeting April 17-22, 2026, in San Diego.
Presentations cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs, and CAR-T, showing how patient-derived models and integrated molecular and functional data aim to reduce translational risk and guide development decisions.
Champions Oncology (Nasdaq:CSBR) appointed Brian Alexander, MD, MPH, to its Board of Directors on March 30, 2026, to advance its data-driven translational oncology strategy. His experience in oncology, data science, and drug development supports Champions' effort to connect patient-derived tumor models with molecular and clinical datasets.
The company intends to use advanced analytics and AI to deepen disease insights, accelerate discovery, and improve translational R&D outcomes by linking PDX tumor models with multi-omic and patient data.
Champions Oncology (Nasdaq:CSBR) reported Q3 fiscal 2026 total revenue of $16.6 million (record study service revenue, +32% year-over-year excluding a prior $4.5M data license). Adjusted EBITDA was $574,000 and GAAP loss from operations was about $276,000. Cash was approximately $7.1 million with no debt.
Costs and operating expenses rose 34.3% year-over-year, driven by outsourced lab services and investments in the data platform and commercial team; management expects margin improvement as radiolabeling moves in-house.
Champions Oncology (NYSE: CSBR) will report third-quarter results for the period ended January 31, 2026, on Thursday, March 12, 2026, after market close. The company will host a conference call the same day at 4:30 P.M. EDT (1:30 P.M. PDT).
Dial-in details: Domestic 888-506-0062, International 973-528-0011, access code 957548. A replay is available for 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode 53731, or via the investors section of the company website.
Champions Oncology (Nasdaq:CSBR) reported record quarterly service revenue of $15.0 million for Q2 FY2026 (period ended Oct 31, 2025), up 11.5% year‑over‑year, and oncology services profit of $7.8 million with a margin of 52% (vs 45% prior year). Adjusted EBITDA was $843,000 and net income was $237,000 for the quarter. Year‑to‑date revenue was $29.0 million (+5.4%) with adjusted EBITDA of $962,000. Cash on hand was approximately $8.5 million and the company reported no debt. Management emphasized investment in its data platform and targeted sales/IT hires while expecting positive adjusted EBITDA for the full fiscal year.